

ERRATUM

Erratum for Wire et al., Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir

Mary Beth Wire,^a Lei Fang,^b Azra Hussaini,^c Joseph F. Kleha,^a Dickens Theodore^a

GlaxoSmithKline, Research Triangle Park, North Carolina, USA^a; PharStat, Research Triangle Park, North Carolina, USA^b; Parexel, Baltimore, Maryland, USA^c

Volume 58, no. 11, p. 6704–6709, 2014. Page 6704: The following sentence should appear at the end of the abstract. “(This study is registered at ClinicalTrials.gov under identifier NCT01657552.)”

Page 6708: The second paragraph of the Acknowledgments section should read as follows. “This research (ClinicalTrials.gov identifier NCT01657552) was sponsored by GlaxoSmithKline, Inc. M. B. Wire, J. Kleha, and D. Theodore were employees of GlaxoSmithKline at the time of the study.”

Citation Wire MB, Fang L, Hussaini A, Kleha JF, Theodore D. 2015. Erratum for Wire et al., Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir. *Antimicrobial Agents and Chemotherapy* 59:2969. doi:10.1128/AAC.00567-15.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.00567-15